Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eric Applebaum

Allergy Parsippany, NJ Medical Doctor

NPI 1336137272 CMS profile 60369

3799 US Highway 46 Ste 205, Parsippany, NJ 07054

Open in the dashboard

General payments

$1,498

72 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eric Applebaum of Parsippany, NJ is reported in the CMS Open Payments database as having received $1,498 across 72 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 42nd percentile of Allergy profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $247 13
2024 General $306 6
2023 General $317 20
2022 General $232 9
2021 General $77 6
2020 General $111 8
2019 General $208 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Applebaum
  • Allergy median
  • Middle half of Allergy
  • National median

In program year 2025, general payments to Eric Applebaum were reported at $247. Among 526 Allergy profiles paid that year, the median was $1,143 and the middle half received between $226 and $2,504.

Show as a table
Year Eric Applebaum Allergy median Middle half National median
2019 $208 $506 $151–$1,337 $163
2020 $111 $409 $108–$1,162 $114
2021 $77 $549 $125–$1,485 $132
2022 $232 $666 $161–$1,594 $149
2023 $317 $780 $186–$1,916 $160
2024 $306 $1,031 $271–$2,196 $164
2025 $247 $1,143 $226–$2,504 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $823 27 payments
  2. GlaxoSmithKline, LLC. $168 17 payments
  3. kaleo, Inc. $113 8 payments
  4. Alexion Pharmaceuticals, Inc. $112 1 payment
  5. Covis Pharma B.V. $98 7 payments
  6. OptiNose US, Inc. $75 5 payments
  7. ALK-Abello, Inc $29 2 payments
  8. Teva Pharmaceuticals USA, Inc. $28 2 payments
  9. Genzyme Corporation $26 1 payment
  10. Mylan Specialty L.P. $13 1 payment
  11. Other $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,486 71 payments
  2. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. FASENRA Respiratory $501 10 payments
  2. AIRSUPRA $382 8 payments
  3. BREZTRI $315 8 payments
  4. FASENRA Respiratory $125 4 payments
  5. TRELEGY ELLIPTA $123 12 payments
  6. SYMBICORT $115 3 payments
  7. AUVI-Q $113 8 payments
  8. SHINGRIX $112 11 payments
  9. AREXVY $112 11 payments
  10. FARXIGA $110 1 payment
  11. Other $440 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

155

Median for Allergy/ Immunology: 449

Drug cost

$8,278

Median for Allergy/ Immunology: $169,700

Branded share of claims

29%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Symbicort Budesonide/Formoterol Fumarate Brand 11 $2,918
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 11 $2,761
Montelukast Sodium Generic 51 $1,104
Esomeprazole Magnesium Generic 13 $539
Albuterol Sulfate Hfa Albuterol Sulfate Brand 11 $317
Fluticasone Propionate Generic 14 $299
Prednisone Generic 32 $236
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 12 $105

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$74,493

Medicare's payments for the services billed

Medicare patients

47

Average age 74

Services billed

5,345

27 women, 20 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 57%
Arthritis 57%
Ischemic heart disease 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $111
$111 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $66
$66 — —
Xhance
  • OptiNose US, Inc. $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

72 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record